Table 1. Characteristics of the study population by HBV coinfection.
| Parameters | HIV-HBV (n = 78) | HIV (n = 40) | P value |
|---|---|---|---|
| Median age (years, IQR) | 38 (35–48) | 42 (35–46) | 0.5 |
| Male sex (n, %) | 8 (20) | 16 (21) | 0.9 |
| Median BMI (Kg/m2, IQR) | 21 (19–24) | 22 (20–25) | 0.4 |
| HIV infection type (n, %) HIV1 HIV2 HIV1+2 |
58 (78) 3 (4) 13 (18) |
34 (90) 2 (5) 2 (5) |
0.2 |
| Median duration since HIV diagnosis (months, IQR) | 34 (14–68) | 66 (20–82) | 0.04 |
| CD4+ T-cell count (n, %) <200 cells/mm3 ≥200 cells/mm3 |
24 (34) 46 (66) |
13 (34) 25 (66) |
1.0 |
| Median CD4+ T-cell count (cells/mm3, IQR) | 293.5 (147–444) | 302 (170–411) | 0.7 |
| HIV RNA (n, %) Undetectable Detectable |
30 (53) 27 (47) |
26 (70) 11 (30) |
0.09 |
| Median HIV RNA (log copies/mL, IQR) | 4.1 (3.2–5.0) | 4.2 (3.2–4.6) | 0.7 |
| HBV DNA (n, %) Undetectable 50–2,000 IU/mL 2,000–20,000 IU/mL ≥2, 000 IU/mL |
1 (1) 46 (60) 12 (16) 18 (23) |
NA | NA |
| Median ALT (IU/L, IQR) | 15 (12–25) | 17 (11–26) | 0.9 |
| Median AST (IU/L, IQR) | 28 (24–40) | 24 (19–30) | 0.004 |
| Median platelet count (x109/L, IQR) | 186 (152–220) | 198 (163–238) | 0.1 |
| APRI (n, %) <0.5 0.5–1.5 ≥1.5 |
29 (39) 38 (51) 7 (10) |
27 (69) 12 (31) 0 |
0.005 |
| Median APRI (IQR) | 0.58 (0.43–0.88) | 0.42 (0.35–0.53) | 0.002 |
| FIB-4 (n, %) <1.45 1.45–3.25 ≥3.25 |
30 (40) 39 (53) 5 (7) |
25 (64) 14 (36) 0 |
0.03 |
| Median FIB-4 (IQR) | 1.72 (1.22–2.34) | 1.35 (1.06–1.63) | 0.004 |
| ART regimen (n, %) Never treated 3TC without TDF TDF |
17 (22) 54 (69) 7 (9) |
5 (13) 29 (74) 5 (13) |
0.5 |
| Duration of 3TC exposure (n, %)*, ** <12 months 12–60 months ≥60 months |
14 (23) 32 (52) 15 (25) |
7 (21) 13 (38) 14 (41) |
0.2 |
*This analysis only includes those who have ever received ART;
**3TC without a second HBV active anti-viral drug
ALT—alanine aminotransferase; APRI—AST to platelet ratio index; ART—antiretroviral therapy; AST—aspartate aminotransferase; BMI—body mass index; HIV—Human Immunodeficiency virus; RNA—ribonucleic acid; TDF—Tenofovir Disoproxil Fumarate; 3TC—Lamivudine